Table 2. Treatment characteristics.
| Characteristics | FEC100 | Epi-Vnr |
|---|---|---|
| Treated patients (n) | 236 | 233 |
| Cycles delivered (n) | 1386 | 1373 |
| Six cycles completed, no. of treated patients (%) | 224 (94.9) | 224 (96.1) |
| Treatement delayed, no. of cycles (%) | 355 (25.6) | 422 (30.7) |
| Cumulative dose, median (range) | ||
| Epirubicin | 600 (100–628) | 300 (97–379) |
| Vinorelbine | NA | 300 (51–387) |
| Mean relative dose intensity, % (s.d.) | ||
| Epirubicin | 89.1 (11.8) | 88.9 (10.2) |
| Vinorelbine | NA | 87.8 (11.2) |
| Mean dose intensity, mg m−2 week−1 (s.d.) | ||
| Epirubicin | 29.9 (3.9) | 15.1 (1.5) |
| Vinorelbine | NA | 14.9 (1.7) |
Epi-Vnr=epirubicin–vinorelbine; NA=not applicable; s.d.=standard deviation.